Patents by Inventor Winton Dennis Jones
Winton Dennis Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7655641Abstract: The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.Type: GrantFiled: February 10, 2004Date of Patent: February 2, 2010Assignee: Eli Lilly and CompanyInventors: Scott Eugene Conner, Lynn Stacy Gossett, Jonathan Edward Green, Winton Dennis Jones, Jr., Nathan Bryan Mantlo, Donald Paul Matthews, Daniel Ray Mayhugh, Daryl Lynn Smith, Jennifer Ann Vance, Xiaodong Wang, Alan M Warshawsky, Leonard Larry Winneroski, Jr., Yanping Xu, Guoxin Zhu
-
Patent number: 7595339Abstract: Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.Type: GrantFiled: August 17, 2007Date of Patent: September 29, 2009Assignee: Eli Lilly and CompanyInventors: Jennifer Rebecca Allen, Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, George Stuart Gregory, Stephen Andrew Hitchcock, Paul J. Hoogestraat, Winton Dennis Jones, Jr., Daryl Lynn Smith
-
Publication number: 20080287504Abstract: Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.Type: ApplicationFiled: August 17, 2007Publication date: November 20, 2008Inventors: Jennifer Rebecca Allen, Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, George Stuart Gregory, Stephen Andrew Hitchcock, Paul J. Hoogestraat, Winton Dennis Jones, JR., Daryl Lynn Smith
-
Publication number: 20080167310Abstract: The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.Type: ApplicationFiled: October 3, 2007Publication date: July 10, 2008Inventors: Lynn Stacy Gossett, Jonathan Edward Green, James Robert Henry, Winton Dennis Jones, Donald Paul Matthews, Quanrong Shen, Daryl Lynn Smith, Jennifer Ann Vance, Alan M. Warshawsky, Maria Rosario Gonzalez-Garcia
-
Patent number: 7282501Abstract: The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.Type: GrantFiled: May 24, 2002Date of Patent: October 16, 2007Assignee: Eli Lilly and CompanyInventors: Lynn Stacy Gossett, Jonathan Edward Green, James Robert Henry, Winton Dennis Jones, Donald Paul Matthews, Quanrong Shen, Daryl Lynn Smith, Jennifer Ann Vance, Alan M. Warshawsky
-
Patent number: 7276516Abstract: Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine.Type: GrantFiled: December 13, 2004Date of Patent: October 2, 2007Assignee: Eli Lilly and CompanyInventors: Jennifer Rebecca Allen, Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, George Stuart Gregory, Steven Andrew Hitchcock, Paul J. Hoogestraat, Winton Dennis Jones, Jr., Daryl Lynn Smith
-
Patent number: 7034045Abstract: The present invention provides certain monofluoroalkyl derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.Type: GrantFiled: April 17, 2000Date of Patent: April 25, 2006Assignee: Eli Lilly and CompanyInventors: David Michael Bender, Buddy Eugene Cantrell, Andrew Hendley Fray, Winton Dennis Jones, William David Miller, David Mitchell, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
-
Patent number: 6911476Abstract: The present invention provides certain sulfonamide derivatives useful for potentiating glutamate receptor function in a patient and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.Type: GrantFiled: February 26, 2001Date of Patent: June 28, 2005Assignee: Eli Lilly and CompanyInventors: Joshua Zwick Davison, Winton Dennis Jones, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
-
Patent number: 6900353Abstract: The present invention provides compounds of formula (I): useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.Type: GrantFiled: September 28, 2001Date of Patent: May 31, 2005Assignee: Eli Lilly and CompanyInventors: Buddy Eugene Cantrell, Winton Dennis Jones, Jr., Timothy Alan Shepherd, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
-
Publication number: 20040198833Abstract: The present invention provides compounds of formula (I), useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.Type: ApplicationFiled: January 30, 2003Publication date: October 7, 2004Inventors: David Michael Bender, Scott Louis Forman, Winton Dennis Jones, Daryl Lynn Smith, Dennis Michael Zimmermann
-
Publication number: 20040097499Abstract: The present invention provides certain amide, carbamate and urea derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.Type: ApplicationFiled: July 3, 2003Publication date: May 20, 2004Inventors: MacKlin Brian Arnold, David Michael Bender, Thomas John Bleisch, Winton Dennis Jones, Paul Leslie Ornstein, Hamid H. Zarrinmayeh, Dennis Michael Zimmerman
-
Publication number: 20040067984Abstract: The present invention provides compounds of formula (I): useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.Type: ApplicationFiled: March 11, 2003Publication date: April 8, 2004Inventors: Buddy Eugene Cantrell, Winton Dennis Jones, Timothy Alan Shepherd, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
-
Patent number: 6713516Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.Type: GrantFiled: December 12, 2002Date of Patent: March 30, 2004Assignee: Eli Lilly and CompanyInventors: Macklin Brian Arnold, David Michael Bender, Andrew Hendley Fray, Winton Dennis Jones, Paul Leslie Ornstein, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
-
Patent number: 6693137Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.Type: GrantFiled: January 23, 2001Date of Patent: February 17, 2004Assignee: Eli Lilly and CompanyInventors: Macklin Brian Arnold, David Michael Bender, Buddy Eugene Cantrell, Winton Dennis Jones, Paul Leslie Ornstein, Richard Lee Simon, Edward C. R. Smith, Eric George Tromiczak, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
-
Publication number: 20030225266Abstract: The present invention provides certain sulfonamide derivatives useful for potentiating glutamate receptor function in a patient and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.Type: ApplicationFiled: August 15, 2002Publication date: December 4, 2003Inventors: Joshua Zwick Davison, Winton Dennis Jones, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
-
Publication number: 20030225127Abstract: The present invention provides certain heterocyclic sulfonamide derivatives of formula (I): useful for potentiating glutamate receptor function in a patient and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.Type: ApplicationFiled: April 1, 2003Publication date: December 4, 2003Inventors: David Michael Bender, Scott Louis Forman, Winton Dennis Jones, Daryl Lynn Smith, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
-
Publication number: 20030220369Abstract: The present invention provides certain heterocyclic sulfonamide derivatives of formula I: useful for potentiating glutamate receptor function in a patient and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.Type: ApplicationFiled: January 13, 2003Publication date: November 27, 2003Inventors: Scott Louis Forman, Winton Dennis Jones, Daryl Lynn Smith, Hamideh Zarrinmayeh, Dennis MIchael Zimmerman
-
Publication number: 20030171350Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.Type: ApplicationFiled: December 12, 2002Publication date: September 11, 2003Inventors: MacKlin Brian Arnold, David Michael Bender, Andrew Hendley Fray, Winton Dennis Jones, Paul Leslie Ornstein, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
-
Patent number: 6617351Abstract: The present invention provides certain amide, carbamate and urea derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.Type: GrantFiled: January 23, 2001Date of Patent: September 9, 2003Assignee: Eli Lilly and CompanyInventors: Macklin Brian Arnold, David Michael Bender, Thomas John Bleisch, Winton Dennis Jones, Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
-
Patent number: 6525099Abstract: The present invention provides certain N-substituted sulfonamide derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.Type: GrantFiled: January 23, 2001Date of Patent: February 25, 2003Assignee: Eli Lilly and CompanyInventors: Macklin Brian Arnold, Winton Dennis Jones, Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman